Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Infection by SARS-CoV-2 elicits antibodies against various domains of the spike protein, including the RBD and NTD of subunit S1 and against subunit S2. The antibody responses of different infected individuals exhibit different efficacies to inactivate (neutralize) the virus.
Article activity feed
-
-
SciScore for 10.1101/2021.08.04.455181: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Collection of plasma and serum from donors and patients: All blood donors were screened following the FDA guidance instructions under an institutional review board approved protocol (IRB #202003554).
Field Sample Permit: At the time of plasma collection, serum samples were collected in serum separator tubes and allowed to clot for at least 30 minutes.Sex as a biological variable The second study group is composed of convalescent plasma collected from women hospitalized for delivery, who had previously been infected by SARS-CoV-2, as confirmed by a SARS-CoV-2-positive PCR (n=7) or positive serology test (n=21). Randomization not detected. Blinding not detected. Power Analysis not detected. Cell … SciScore for 10.1101/2021.08.04.455181: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: Collection of plasma and serum from donors and patients: All blood donors were screened following the FDA guidance instructions under an institutional review board approved protocol (IRB #202003554).
Field Sample Permit: At the time of plasma collection, serum samples were collected in serum separator tubes and allowed to clot for at least 30 minutes.Sex as a biological variable The second study group is composed of convalescent plasma collected from women hospitalized for delivery, who had previously been infected by SARS-CoV-2, as confirmed by a SARS-CoV-2-positive PCR (n=7) or positive serology test (n=21). Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Commercial immunoassays to measure antibodies that target SARS-CoV-2 proteins: The DiaSorin Liaison SARS-CoV-2 S1/S2 IgG chemiluminescence assay detects IgG against spike subunits S1 and S2. S2suggested: NoneThe Ortho COVID-19 IgG antibody test was performed on Ortho’s VITROS® system. COVID-19 IgGsuggested: NoneExperimental Models: Cell Lines Sentences Resources Cells lines: Vero-E6 cells, human embryonic kidney (HEK) 293T cells and human osteosarcoma (HOS) cells were obtained from the American Type Culture Collection (ATCC). HEKsuggested: NoneAll proteins were produced by transient transfection of 293T cells using polyethyleneimine (PEI), as previously described (46). 293Tsuggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)To propagate virus, Vero-E6 cells cultured in DMEM/FCS 2% were infected at a multiplicity of infection (MOI) of 0.001. Vero-E6suggested: NoneRecombinant DNA Sentences Resources Briefly, HOS cells were seeded in white opaque 96-well plates (1.4 × 104 cells per well) and transfected the next day with 80 ng per well of pCG1-SARS-2-S plasmid expressing SARS-CoV-2 spike using JetPrime transfection reagent. pCG1-SARS-2-Ssuggested: NoneSoftware and Algorithms Sentences Resources These values, along with the log-transformed dilution values were fit to a non-linear regression model using GraphPad Prism 8 to calculate the IC50 value. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- No conflict of interest statement was detected. If there are no conflicts, we encourage authors to explicit state so.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
